Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform

Summary

Moderna announced at its Science Day new pipeline programs in in vivo CAR-T and solid tumor oncology, along with an AI-driven research platform designed to accelerate drug discovery across its pipeline, signaling strategic expansion beyond vaccines and rare disease.